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ABSTRACT 
 
Exploring the Functional Interaction between CaMK-II and p53  
By Raymond E. Lai, B.S. 
A Thesis submitted in partial fulfillment of the requirements for the degree of Master of Science, 
Biology at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2011 
 
Major Director: Robert M. Tombes, Ph. D 
Professor, Department of Biology 
 
 Calcium (Ca2+)/calmodulin-dependent kinase 2 (CaMK-II) is a multifunctional member 
of a family of Ca2+/calmodulin-dependent serine/threonine protein kinases that respond to 
transient intracellular calcium signaling. CaMK-II has been reported to be involved with 
transcription regulation, cell motility, neuronal development, cell cycle regulation, and more 
recently early development of vertebrates (Easley et al., 2008; Rothschild et al., 2009; 
Francescatto et al., 2010). Through previous work in the lab using tandem mass spectrometry 
and “substrate-trapping mutants”, tumor suppressor protein 53 (p53) was identified as a novel 
CaMK-II binding partner in tissue culture. In this study, I sought to provide characterization of 
the functional interaction of p53 and CaMK-II. First, a stable p53 knockdown human cell line 
(HEK) was established through lentiviral transduction of p53 shRNA and verified with 
immunoblots and immunostaining assays. Next, the localization of CaMK-II and the cell growth 
rate in these cells was determined. In wild type HEK cells, catalytically inactive CaMK-II 
inhibited cell growth, which is consistent with previous studies in mouse fibroblasts with 
ix 
 
pharmacological inhibition. p53-deficient cells were less sensitive to CaMK-II deficiencies using 
dominant negative CAMK-II, but not pharmacological disruption. The overall results of this 
study have provided significant clues to the mechanism between CaMK-II and p53 in the control 
of cell cycle progression.  
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INTRODUCTION 
 
 
 Calcium (Ca2+)/calmodulin-dependent kinase 2 (CaMK-II) is a multifunctional member 
of a family of Ca2+/calmodulin-dependent serine/threonine protein kinases that respond to 
transient intracellular calcium signaling (Hudmon et al., 2002). CaMK-II is a ubiquitously 
expressed dodecameric enzyme that is encoded by four different genes (α, β, γ, and δ) that form 
over 40 splice variants (Tombes et al., 2003). Each subunit is made up of three different domains: 
the catalytic, variable, and association domains. The amino-terminal catalytic domain encodes 
the calmodulin and autoinhibitory binding regions and is integral for ATP and substrate binding. 
With its susceptibility to alternative splicing, the variable domain is responsible for the diversity 
of the kinase. The oligomerization of its monomers to form a dodecomeric protein takes place on 
the carboxy-terminal association domain. CaMK-II oligomerization enables it to be 
autophosphorylated independently of Ca2+ when Ca2+ levels subside within the cell (Kolb et al., 
1998; Lantsman and Tombes, 2005).   
 
 Roles of CaMK-II. Inherent of its own transcriptional and post-transcriptional variability, 
CaMK-II binds to and phosphorylates a number of different target substrates. Because of this, it 
is an enzyme with a wide array of functions (Yoshimura et al., 2002). As indicated in previous 
literature, CaMK-II has been implicated in a variety of roles including cell cycle progression, 
regulation of β-catenin dependent transcription, and promoting cell motility (Easley et al., 2008; 
Seward et al., 2008). From some recently published work, CaMK-II has been shown to be 
essential for the early development of vertebrates. A specific member of the CaMK-II family (β2 
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CAMK-II) is induced by T-box transcription factor (Tbx-5). Tbx-5 is a protein known to be 
expressed during atrium and ventricle development in the heart of zebrafish and when mutated in 
humans result in limb and heart abnormalities typically described by the autosomal dominant 
disorder known as Holt-Oram syndrome (Basson et al., 1997; Rothschild et al., 2009). The 
expression of β2 CAMK-II is also in the developing fins and the looping of the heart, but is 
diminished in tbx-5 morphants. In both zebrafish embryos and mouse fibroblast cells, CaMK-II 
expression is significantly increased upon the introduction of excess Tbx-5.  CaMK-II is thus 
dependent on Tbx-5 and is necessary for heart and fin development (Rothschild et al., 2009). 
Additional work on zebrafish has also shown that activated CaMK-II is identified as a target of 
Ca2+ elevations that occur on the left side of the Kupffer’s vesicle (KV) during development. The 
transient activation of CaMK-II linking KV function with lateral plate mesoderm signaling has 
been shown to be responsible for left-right asymmetry in zebrafish. Fluid flowing 
counterclockwise over adjacent ciliated cells or morphogen binding induces Ca2+ elevations on 
the left side of the KV. Membrane targeted hetero-oligomers of αKAP and γ1 CaMK-II are 
activated through further Ca2+ elevations by PKD2 dependent calcium release via cilia, ER and 
the ryanodine receptor, Ryr3. Ca2+ elevation into the adjacent cells in the KV via connexin gap 
junctions and the subsequent clustering of activated CaMK-II induces left-right asymmetry 
through southpaw processing or secretion (Francescatto, 2010). 
 CaMK-II, known to co-localize with the actin cytoskeleton, has also been implicated to 
induce cell motility through focal adhesion turnover. Paxillin and focal adhesion kinase (FAK), 
two proteins known to be critical in structure in focal adhesion complexes, are actively 
dephosphorylated by the catalytic activity of CaMK-II promoting focal adhesion disassembly 
and thus increases cell motility (Easley et al., 2008).   
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 The role of CaMK-II during cell cycle progression and β catenin dependent gene 
regulation has also been studied. Active CaMK-II binds with the gelsolin-related actin binding 
and capping protein, Flightless-I (Fli-I), and sequesters it in the cytosol. When CaMK-II is 
inhibited, Fli-I detaches and translocates into the nucleus thereby disrupting DNA synthesis by 
lowering the levels of β catenin dependent genes including cyclin D1. When cyclin D1 levels 
drop, the cell arrests in G1 and thus cannot proceed toward the S phase of the cell cycle (Seward 
et al., 2008; Resnitzky et al.,1994). Another recently published study has shown that inhibited 
CaMK-II causes G1 cell cycle arrest by reducing cyclin D1 levels and enhancing the association 
with p27Kip1 with Cdk2 (Morris et al., 1998).  
 
 Substrate-Trapping Mutants. Historically studying protein-protein interactions within a 
signaling cascade has been difficult due to the high complexity of the phosphorylation and 
dephosphorylation activities performed by kinases and phosphatases, respectively. “Substrate 
trapping” phosphatases that lack their catalytic activity but maintain their substrate binding 
ability were developed in the past and used to study protein interactions. Following the co-
precipitation of phosphatase substrates with the inactive phosphatase, the identification of both 
proteins by mass spectrometry was possible (Blanchetot et al., 2005).  
In previous work done by Ali Myers of the Tombes Lab, substrates of CaMK-II were 
identified and isolated using catalytically inactive CaMK-II as “bait”. Several mutant CaMK-II 
with different functions were created which include K43A, K43G, D137A, D189A, and T287D. 
Phospho-transfer is an activity that lysine (K) located on the 43rd position of the CaMK-II 
catalytic domain participates in (Hanks et al., 1988). When this residue is altered, it can have a 
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profound effect on its ability to phoshorylate its substrates. Some of the mutants that have been 
constructed have this specific residue changed from one that was large and negatively charged to 
one that is smaller and neutral like alanine or glycine. The resulting K43A and K43G CaMK-II 
mutants retain their high affinity for their substrates, but have lost their ability to complete the 
catalytic cycle, which therefore causes substrate trapping at their active sites (Figure 1). The 
catalytically inactive K43A and K43G CaMK-II constructs in conjunction with tandem mass 
spectrometry were utilized in order to isolate and identify p53 as a novel CaMK-II binding 
partner.  For this study, the use of these “substrate-trapping” mutants was essential in 
determining the functional role of CaMK-II with p53 in tissue culture.  
 
 Roles of p53. Tumor suppressor protein p53 is often described as the “guardian of the 
genome” referring to its significant contribution in preventing genomic mutation by conserving 
stability (Lane, 1992). The p53 protein is involved in several anti-cancer mechanisms which 
include roles in apoptosis, genetic stability, growth arrest, and even the inhibition of 
angiogenesis (Muller et al., 2011). It should be noted that the majority of cancer related illness is 
attributed to some form of p53 mutation, gene deletion, or abrogated cellular component in the 
p53 pathway (Amaral et al., 2010). p53 stabilization like most other proteins happen upon a 
phosphorylation event by a kinase such as JNK, p38, and ATM. The stabilization of p53 is 
regulated by the E3 ubiquitin ligase, mdm2, which acts by inactivating the tumor suppressor 
through nucleus exportation and its subsequent degradation by the 26S proteosome (Brooks et al., 
2007). When p53’s lysine residues are acetylated, ubiquitination events of p53 are reduced (Li et 
al., 2002). Activated p53 is most known for suppressing tumor formation by binding to DNA 
5 
 
which activates the expression of genes like WAF1/CIP1 that encode for the protein p21. When 
p21 binds to and forms a complex with Cdk-2, the cell cycle arrests between the G1 and S phases 
(Abbas et al., 2009). p53 is also known to induce apoptosis through its mitochondrial pathway.  
In response to a stress signal, p53 is targeted to the mitochondria and interacts with anti- and pro-
apopotic Bcl-2-family members either inhibiting or activating them. This at first leads to robust 
mitochondrial outer membrane permeabilization then is followed by the initiation of caspase 
activity. Apoptosis can also be generated via the death receptor pathway which occurs by the 
recruitment of adapter proteins by receptors in the cellular membrane which also trigger the 
activation of caspases (Amaral et al., 2010). 
 
  siRNA and shRNA Lentiviral Transduction. The latest advances in sequence-based 
approaches to “knockdown” gene function have given rise to a wide array of cost-effective 
reverse genetic approaches for studying gene function. This study utilized the approach 
involving lentiviral mediated transduction to stably knockdown the p53 gene by delivering 
shRNA into cells. shRNA which goes through the RNAi mechanism in cells has been proven to 
be applicable to a number of organisms and has been used to generate a wide array of loss-of-
function phenotypes (Kuttenkeuler and Boutros, 2004). Lentiviruses can deliver a significant 
amount of genetic information into the DNA of the host cell and have the unique ability among 
retroviruses of being able to replicate in non-dividing cells.  Unlike other retroviruses which can 
only affect dividing cells, the pre-integration complex of lentiviruses can penetrate the intact 
membrane of the nucleus of the target cell. Lentiviral transduction integrates the shRNA into the 
chromosome of the target cell. The resulting shRNA produced by the transcriptional machinery 
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of the cell will then translocate to the cytoplasm where it binds to and gets cleaved by the Dicer 
endonuclease into single stranded small interfering RNA (siRNA). The RNA induced silencing 
complex (RISC) then cleaves the target mRNA that is complementary with the siRNA 
(Pattanayak et al. 2005). This technology was used to create a stable p53 knockdown human 
embryonic kidney (HEK) tissue culture cell line. The utilization of this newly established HEK 
cell line was a key component in my investigation of characterizing the functional interaction 
between CaMK-II and p53.  
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MATERIALS AND METHODS 
 
 mPCT and HEK Cell Culture. Dulbecco Modified Eagle’s Medium (DMEM) with 10% 
FBS, L-Glutamine, Pennicilin Streptomycin was used to maintain mouse proximal convoluted 
tubule (mPCT) and human embryonic kidney (HEK) cell lines incubated at 37°C with 5% CO2 
in 100mm dishes. 3µg/mL of filtered puromycin (InVivoGen, San Diego, CA) diluted in 1x 
HBSS was included in the medium for maintaining the p53 RNA and GFP RNA infected HEK 
cell line. Cells were sub-cultured every 3-4 days to maintain sub-confluence.  
 
Vectors. Lys-43-Ala (K43A) and Lys-43-Gly (K43G) were introduced via PCR mediated 
site-specific mutagenesis into the coding sequence for FLAG-GFPδe CaMK-II. The mutant 
constructs were directionally inserted into the pCDNA3 vector for transfections. Vectors were 
confirmed through restriction enzyme digestion, DNA sequencing and protein expression was 
determined through immunoblotting.  
 
Transfection into Cell Lines. Transfection of the mutants with a total of 3µg plasmid 
DNA using Lipofectamine 2000 (Invitrogen, Carlsbad, CA) diluted in Opti-MEM (Invitrogen) 
were performed on human embryonic kidney cells (HEK) and mouse proximal convoluted 
tubules (mPCTs) cell lines at 50-70% confluency in 6 well plates (Corning Inc, Corning, NY). 
pBlueScript-KS+ (BS) was co-transfected if necessary as a carrier vector. p53 siRNA and p53 
scrambled siRNA (Sigma-Aldrich, St. Louis, MO) was double transfected into HEK cell lines 24 
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hours apart before being transfected by CaMK-II constructs. Cells were re-fed with culture 
medium (DMEM, as described in cell culture section) just prior to the addition of transfection 
agents.  
 
siRNA. siRNA provided by Dr. Sumitra Deb of the VCU Medical Center (up to 40 pmol) 
were transfected with a total of 3.0 µg of pBluescript KS+ or other DNA vector into HEK cells 
using Lipofectamine 2000 as described under transfections. The p53 siRNA and p53 scrambled 
siRNA (Sigma-Aldrich) are listed from 5’ to 3’.  
p53 siRNA: GCA UGA ACC GGA GGC CCA U  
p53 scrambled siRNA: CAU GUC AUG UGU CAC AUC UC 
 
Lentiviral Generation and Transduction. 5µg of shRNA (either p53 or GFP control) 
constructs with 2.5µg of a packaging vector and 2.5µg of an envelope vector (Sigma-Aldrich) 
were co-transfected into HEK cells as described in the transfection section.  After 48 hours of 
incubation at 37°C with 5% CO2, the medium containing the recombinant lentiviral particles 
from the transfected cells was collected. HEK cells in a 100mm plate were washed with 1x PBS 
then treated with 1 mL of the lentiviral medium. The cells were incubated at 37°C with 5% CO2 
with gentle rocking every 15 minutes for 2 hours. 10 mL of complete media was added and 
incubated for 48 hours before they were selected with 4µg/mL of puromycin antibiotic. All the 
work involving the lentiviral generation and transduction was kindly performed by Catherine 
Vaughn of Dr. Sumitra Deb’s lab of the VCU Massey Cancer Center in Richmond, Virginia. 
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Immunostaining. Cells were prepared for immunostaining by being sub-cultured on 
poly-D-lysine (Fisher Scientific, Pittsburgh, PA) pre-treated 12 mm cover slips (Fisher Scientific) 
in 6 well plates (Corning Inc). Cells which were approximately 70% confluent were washed with 
1x PBS, fixed with 4% Paraformaldehyde in 1x PBS for 10 minutes, and washed with 0.01% 
NP40 in 1x PBS. The cells were then fixed again with 4% Paraformaldehyde in 1x PBS for 5 
minutes, washed with 1x PBS then blocked with 5% BSA in 1x TBSTA for 1 hour at room 
temperature. The appropriate primary antibody was diluted to 10µg/mL with 2% BSA in 1x 
TBSTA and incubated with the cells at 37°C for 1 hour. Cells were washed three times for 5 
minutes with 1x PBS. The appropriate secondary antibody was diluted to 10µg/mL in 2x BSA in 
1x TBSTA and applied to the cells for 30 minutes at 37°C. Cells were washed three times for 5 
minutes with 1x PBS and placed on slides with mounting medium for imaging (KPL, 
Gaithersburg, MD).  
 
DAPI Staining. 4',6-diamidino-2-phenylindole (DAPI) is a fluorescent stain that binds 
strongly to nuclear DNA. A solution containing 4% Paraformaldehyde in 1x PBS, 0.05% NP40, 
and 5µg/mL DAPI was made and applied to the cells and incubated at 4°C for 30 minutes.  Cells 
were then washed and stored in 1x PBS for imaging.  
 
Mitochondrial Staining.  1mM of MitoTracker (Invitrogen) stock solution was diluted to 
100nM in culture medium (DMEM, as described in the cell culture section). Once cells reached 
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70% confluency, media was removed and pre-warmed staining solution containing the 
MitoTracker probe was added and put in a 5% CO2 incubator for 30 minutes set to 37°C. 
Mitochondrial staining of the cells were then verified using a fluorescent microscope then fixed 
using 4% Paraformaldehyde in 1x PBS for 10 minutes. 
 
Cell Harvest. mPCTs were harvested as follows: 0.25% Trypsin-EDTA added and 
resuspended in culture medium (DMEM, as described in the cell culture section). The cells were 
then washed with 1x Phosphate Buffered Saline (PBS, Gibco/Invitrogen,), centrifuged at 1000 x 
g for 5 min at 4°C, and resuspended in homogenization buffer containing 20mM HEPES (pH7.4), 
2.6mM EGTA, 20mM MgCl2 and 80mM β-glycerol phosphate with 1µg/µL okadaic acid, and 
1µg/ml protease inhibitors (chymostatin, leupeptin, aprotinin, pepstatin, and soybean trypsin 
inhibitor (SBTI)). Cells were sonicated twice with 3 second bursts on ice then centrifuged at 
12,000 x g for 5 minutes. HEK cells were harvested the same way but without the addition of 
0.25% trypsin-EDTA.  
 
Western Transfer and Immunoblotting. Cell lysates were subject to Sodium Dodecyl 
Sulfate- Polyacrylamide Gel Electorphoresis (SDS-PAGE) using the Bio-Rad Mini-Protean 
System. Western protein transfer was separated using 4-15% polyacrylamide gels at 150V and 
then transferred on to 0.45µm pore size nitrocellulose medium (Bio-Rad, Hercules, CA) for 1 
hour at 110V. Proteins on nitrocellulose were blocked with 5% BSA in 1x TBSTA (0.05% 
Tween 20, 0.05% Sodium Azide) for 30 min. The appropriate primary antibody was diluted to 
1µg/mL in 5% BSA then added to the nitrocellulose paper for about 18 hours rocking overnight 
11 
 
at room temperature. Three 5 minute washes were performed with 1x TBSTA then 2µg/ml of 
alkaline phosphatase conjugated secondary antibody was added and shaken for 2 hours. Blots 
were then washed three times for 5 minutes with 1x TBSTA before being developed in 0.1 M 
Tris, 0.1 M NaCl, 5mM MgCl2 phosphatase buffer (pH 9.4) containing 0.25 mg/ml 5-bromo-4-
chloro-3-indolyl phosphate (BCIP, Sigma-Aldrich) and 0.25 mg/ml nitro blue tetrazolium (NBT, 
Sigma-Aldrich) in the dark. Selected blots were digitally scanned.  
 
Antibodies. The mouse anti-p53 monoclonal antibody (1C12) was purchased from Cell 
Signaling Technology, Danvers, MA. Goat anti-mouse and Rabbit anti-mouse secondary 
antibodies were purchased from Invitrogen.  
 
Drug treatment. KN-93, a membrane permeant calmodulin antagonist CaMK-II inhibitor 
(Fisher Scientific) was directly added to cells in culture at various concentrations diluted in 
culture medium.  
 
Imaging. A 12-bit camera and an Olympus IX-70 inverted microscope was used in order 
to capture phase contrast and fluorescent images (Olympus, Melville, NY). Fluorescent images 
were taken with two second exposures using a 595 nm dichroic long pass filter (Chroma, 
Rockingham, VT) illuminated by a mercury arc lamp. The images were processed using 
Olympus Microsuite, v.5.  
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RESULTS 
 
 Knockdown and verification of p53 stable cell lines. To begin the investigation of the 
functional interaction of CaMK-II and p53, a stable p53 knockdown cell line was established. 
The HEK cell line was chosen since they have good transfection efficiency (60-70%). The 
stable HEK cell line was made using lentiviral transduction of shRNA to knockdown p53. An 
additional lentiviral transduction was performed with GFP shRNA to establish a virally infected 
control HEK cell line. Each shRNA vector contained a gene resistant to the antibiotic 
puromycin for selection. Following the generation of the viral particles and the subsequent 
transduction (as described in the methods section), multiple clones were selected using 
puromycin antibiotic and then grown to full confluence. Immunoblots and an immunostaining 
assay verifying p53 knockdown using mouse monoclonal antibodies specific to p53 were 
performed on the lysates obtained from the harvest of each shRNA infected HEK cell line 
(Figure 2A and B). These tests confirmed the successful knockdown of p53 in the HEK cell line 
and thus could be used for further analysis. 
 
K43G CaMK-II inhibits cell growth in the presence of p53. Cell cycle arrest has been 
reported to be linked to CaMK-II inhibition through both the transition from G1 to S and G2 to M 
phases (Tombes et al., 1995; Morris et al., 1998). In order to observe the effect of CaMK-II on 
cell cycle regulation in p53 deficient cells, HEK cells were DAPI stained 48 after WT or K43G 
CaMK-II construct transfection. The cells counted in ten random fields for each condition were 
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summed then averaged amongst three different experiments. The percent total cell difference 
between WT and K43G transfection was calculated and compared between the p53 knockdown 
and GFP control HEK cell lines. Across all experiments, cells transfected with K43G CaMK-II 
had a lower total cell count compared to those transfected with WT CaMK-II. This result 
suggests that the over expression of dominant negative CaMK-II causes the inhibition of cell 
growth which is consistent with previous work done by pharmacologically inhibiting CaMK-II in 
mouse fibroblasts (Tombes et al., 1995). The percent difference in total cells between WT and 
K43G transfected HEK cells with p53 knocked down was more than two times reduced when 
compared to the control cells. This result suggests that cell growth inhibition only occurs in HEK 
cells that have p53 (Figure 3).  
 
HEK cell growth is repressed by KN-93 induced CaMK-II inhibition, but is not more 
sensitive in the absence of p53. KN-93, a membrane permeant synthetic inhibitor of CaMK-II 
that inactivates CaMK-II activity by antagonizing calmodulin binding, was used in a previous 
study to conclude that CaMK-II is required for cell cycle progression through the G1 phase in 
NIH/3T3 cells (Tombes et al., 1995). CaMK-II inhibition is also involved in the up-regulation of 
the cell cycle inhibitor p21 and down-regulation of the positive regulators cyclin D1, cyclin E, 
and Cdk2 in human ovarian cell lines (Ma et al., 2009). Additionally, upon CaMK-II inhibition 
p53 pathway components such as p21and mdm2 are induced and degraded, respectively, as seen 
in vascular smooth muscle proliferation studies (Li et al., 2011). In order to further examine 
whether CaMK-II inhibition reduces cell growth, KN-93 was used to treat the stable p53 
knockdown HEK cell line in a dose dependent manner in two different experiments (Figure 4A 
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and B). In the initial experiment, HEK cells were treated with KN-93 then DAPI stained after 48 
hours. The total cells counted in fifteen random fields in each condition were summed then 
averaged amongst three different experiments. The percent total cell difference between the KN-
93 treated and untreated HEK cells was calculated and compared between the p53 knockdown 
and GFP control HEK cell lines. Compared to controls, KN-93 treated HEK cells consistently 
had lower total cell number after 48 hours; however, there was no evidence of a significant 
difference between the p53 knockdown and control cells (Figure 4A).  
An additional experiment was done to confirm this result. Direct cell counts were done in 
the presence of KN-93 before treatment then again after 24 hours for each condition. The total 
cells in ten random fields in each condition were summed then averaged amongst two 
experiments. The percentage of total cell increase from when the cells were initially plated to 24 
hours after drug treatment was calculated and compared between the p53 knockdown and GFP 
control HEK cell lines. In the presence of KN-93, HEK cell growth inhibition occurred in a dose-
dependent manner, but again did not show that the p53 deficient cells were more sensitive 
(Figure 4B). 
 
Less CaMK-II aggregates form in absence of p53.  Full length CaMK-II is known to 
localize to the cytosol which was confirmed using fluorescent microscopy (Caran et al., 2001). 
An observation that is consistent across all transfections was the apparent increase of the GFP 
expression of CaMK-II in small aggregates (approximately 1-2 µm in size) in cells transfected 
with dominant negative forms of CaMK-II, K43A and K43G, in both HEK and mPCT cells 
(Figure 5). FLAG-GFP δe CaMK-II K43A transfected cells overall displayed less aggregates in 
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comparison to FLAG-GFP δe CaMK-II K43G. The aggregate analysis was first analyzed using 
siRNA to knockdown p53 in HEK cells. It was necessary to optimize the siRNA transfection in 
order to effectively knockdown p53. The siRNA transfection protocol was conducted by doing a 
double transfection (first transfection = 30 pmol; second transfection = 10 pmol) of p53 siRNA 
or the control p53 scrambled siRNA into HEK cells. WT or K43G CaMK-II was co-transfected 
with the second siRNA transfection. There was a noticeable decrease of CaMK-II aggregates in 
cells with p53 knocked down in both WT and K43G transfected HEK cells at 48 hours post 
transfection (Figure 6A). Amongst the K43G transfected cells, the total number of aggregates in 
the cells with p53 knocked down were reduced by half compared to the p53 scrambled siRNA 
control. Follow up experiments were performed by transfecting the CaMK-II constructs into 
stable p53 knockdown HEK cells. At 48 hours post transfection, the results were consistent with 
the siRNA transfection results. There was a significant difference in the amount of K43G and WT 
CaMK-II aggregates between the p53 knockdown and GFP control HEK cells. The number of 
aggregates was summed from at least ten different fields per condition then averaged between 
three experiments (Figure 6B). 
 
K43G CaMK-II aggregates might not be associated with the mitochondrial p53 pathway. 
The p53 mitochondrial pathway has been described to involve p53 translocating to the 
mitochondria in the cytosol and interacting with a number of anti and pro-apoptotic Bcl-2-family 
members to either initiate or inhibit them.  These interactions lead to eventual mitochondrial 
outer membrane permeabilization and the eventual increase of caspase activity which initiate 
chromatin degradation (Vaseava and Moll, 2008). The initial thought of CaMK-II aggregates 
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occurring within the cytosol of the cells prompted us to think about the possibility that CaMK-II 
might be co-localizing with intracellular mitochondria and thus be involved with the p53 
mitochondrial pathway. To test this, the mitochondrion selective probe MitoTracker from 
Invitrogen was used to stain all intracellular mitochondria in live CaMK-II transfected HEK cells 
which worked by passively diffusing across the plasma membrane and accumulating in active 
mitochondria. Following analysis via fluorescent microscopy, CaMK-II aggregate co-
localization with mitochondria was not clearly evident (Figure 7). Furthermore, there was also no 
clear evidence of DNA fragmentation in dominant negative CaMK-II transfected HEK cells 
which normally occurs upon the initiation of apoptosis (Figure 8). These results do not support 
the possible association of CaMK-II with the mitochondrial p53 dependent mechanism. The 
effects of the functional interaction between CaMK-II and p53 therefore suggest a role in cell 
cycle control. 
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DISCUSSION 
 
The rapid and efficient detection of substrates and binding partners of substrate trapping 
FLAG-GFP δe CaMK-II mutants that were used in a previous investigation done by Ali Myers of 
the Tombes Lab involving tandem mass spectrometry were utilized in this study in an attempt to 
provide evidence of a direct link between the functional interaction of CaMK-II and its recently 
discovered binding partner p53. Despite the lack of evidence showing that p53 is phosphorylated 
by CaMK-II, the binding interaction of p53 to catalytically inactive CaMK-II was previously 
shown. The interaction in this study was characterized using siRNA and lentiviral shRNA 
technology to knockdown p53 transiently and stably, respectively. Tumor suppressor protein p53, 
known to be mutated in most cases of cancer, has been widely studied in order to elucidate its 
roles in apoptosis, genetic stability, and cell cycle regulation (Amaral et al, 2010). CaMK-II has 
also been implicated in cell cycle control and apoptosis in several studies (Li et al., 2009; Wang 
et al., 2008; Tombes et al., 1995). The novel binding interaction between the two proteins 
therefore does not seem to be coincidental considering the similarities in their roles within the 
cell.   
The results obtained in this investigation, provide clues to suggest a model by which 
catalytically inactive CaMK-II sequesters p53 in the cytosol to regulate cell cycle progression 
(Figure 9). Initially, p53 cytosolic localization was expected to cytoprotect or promote cell 
survival similarly to its nuclear exportation mechanism regulated by the stabilization of its 
inhibitor E3 ubiquitin ligase mdm2 (Lohrum et al., 2001). However, from the results obtained in 
my study, the sequestering of p53 by catalytically inactive CaMK-II in the cytosol seems to 
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promote cell cycle arrest and not apoptotic activity. Mitochondria staining did not show clear co-
localization with CaMK-II aggregates (Figure 7) and DAPI staining did not show any evidence 
of nuclear fragmentation (Figure 8).  
Previous studies involving GSK-3 could explain how CaMK-II and p53 work in 
conjunction to regulate cell cycle progression. GSK-3α and GSK-3β are deactivated from the 
phosphorylation of its amino terminal residues Ser21 and Ser9, respectively (Cohen et al., 2001). 
GSK-3β Ser9 and GSK-3α Ser21 are consensus CaMK-II phosphorylation sites and thus activated 
CaMK-II can inactivate GSK-3 through phosphorylation (Song et al., 2010). When CaMK-II is 
inactive, phosphorylation of GSK-3β does not occur and therefore remains activated. Activated 
GSK-3 enters the nucleus and down regulates SKP2, a protein that normally inhibits p27Kip1 
expression.  Stabilized p27Kip1 then binds to cyclin dependent kinase 2 (Cdk2) causing cell-cycle 
arrest at the G0/G1 phase (Wang et al., 2008). A study done using NIH/3T3 cells showed that 
Cdk2 kinase phosphorylates p53 at Ser315 (Price et al., 1995). It has also been shown that 
phosphorylation of proteins by Cdk2 initiates their export from the nucleus (Fradet-Turcotte et 
al., 2010). Upon activation it is possible that Cdk2 initiates the nuclear export of p53 by 
phosphorylating the tumor suppressor at Ser315. However, since Cdk2 is bound to p27Kip1 in my 
proposed model, this may not occur. The mechanism by which explains how p53 is exported 
from the nucleus thereby remains to be determined.   
The results of my study obtained from transfecting cells with catalytically inactive K43G 
CaMK-II seem to support this potential model, however, the importance of the CaMK-II 
aggregates that inevitably form remains to be determined. It can be speculated from the data I 
obtained that once p53 has translocated in the cytosol, catalytically inactive CaMK-II come 
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together to form aggregates localizing in the areas where most of the p53 is found. They might 
do this in order to ensure tight sequestration of the tumor suppressor protein. In the absence of 
p53, CaMK-II will therefore not form aggregates since its tumor suppressor substrate is not 
available to form a binding interaction (Figure 5A and B). Although my results show that 
CaMK-II aggregates do not completely co-localize with mitochondria (Figure 7), there could still 
be some form of interaction with the Bcl-2 family proteins that comprise and drive the 
mitochondrial p53 apoptotic pathway following prolonged G0/G1 cell arrest induced by the up 
regulation of p27Kip1. A recent study has shown that CaMK-II clustering or self-association in 
neuronal cells form under ischemic conditions: low pH, low ATP levels, and the presence of 
Ca2+/Calmodulin. When calmodulin binds to the regulatory region exposing the catalytic 
domains of CaMK-II, the autoinhibitory arm interacts with Thr286 on a CaMK-II monomer of an 
adjacent holoenzyme forming an inter-holoenzyme interaction (Vest et al., 2009). Another study 
using a mammalian kidney cell line showed that CaMK-II self-association is regulated by 
cellular pH and Thr286 autophosphorylation and has variable rates of dissociation depending on 
Ca2+ levels. Their data supports a novel mechanism for targeting CaMK-II to postsynaptic sites 
after neuronal activation forming a scaffold that recruits and localizes additional proteins to the 
postsynaptic density (Hudmon et al., 2005).  It is possible that catalytically inactive CaMK-II 
could be acting in similar fashion by clustering in order to form a scaffold to recruit other 
proteins which aid in sequestering p53 in the cytosol.   
The results that I obtained from the inhibition of CaMK-II using the chemical inhibitor 
KN-93 seems to also follow this model. However, because there was no evidence showing a 
significant difference between p53 knockdown and control HEK cells, the claim to support 
mitochondrial induced p53 apoptosis is less strong. In spite of this, the result is consistent with 
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previous work showing that KN-93 induces G1 cell cycle arrest and could eventually lead to 
apoptosis following extended exposure to the drug (Tombes et al., 1995). Since KN-93 does not 
directly inhibit the catalytic activity of CaMK-II, pre-activated CaMK-II autophosphorylating 
independently of bound Ca2+ and CaM is unaffected by KN-93 inhibition (Schulman et al., 1992). 
KN-93 does not completely inactivate CaMK-II and therefore may not interact in the same way 
that dominant negative K43G or K43A CaMK-II mutants do with p53. 
Another protein that could be involved with p53 and CaMK-II interaction is focal 
adhesion kinase (FAK). It has been shown that cell motility is inhibited upon FAK 
dephosphorylation by activated CaMK-II (Easley et al., 2008). Interestingly, FAK has also been 
implicated to bind to p53 in the cytoplasm (Cance and Golubovskaya, 2008). The overall reasons 
as to why FAK bind to p53 is unclear.  It could be possible that when CaMK-II is inactivated, 
phosphorylated FAK stabilizes p53 thereby giving it the freedom to bind to CaMK-II in the 
cytosol. 
 In all, my thesis work has provided some initial insight to the functional understanding 
of the novel protein-protein binding interaction between CaMK-II and p53. I have also been able 
to assist in optimizing DNA and siRNA transfection protocols that will help expedite the process 
of making discoveries in future tissue culture studies in the lab.  Additionally, I have developed 
not only more relatively efficient, but also reliable methods in obtaining, calculating, analyzing, 
and presenting numerical data acquired from fluorescent and phase contrast microscopic tissue 
culture images. The model that I have proposed from the data I have obtained in my project 
should be especially valuable in the planning of any future functional studies of CaMK-II and 
p53.   
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Figure 1. CaMK-II substrate trapping mutant structure.  CaMK-II contains an amino-terminal 
catalytic domain, variable domain, and a carboxy-terminal association domain. The K43A/G 
point mutation was constructed in a previous project via PCR-mediated site-specific mutagenesis 
into the coding sequence of FLAG-GFP δe CaMK-II. 
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A. 
 
 
 
 
B. 
 
 
Figure 2. Stable p53 knockdown HEK cell line established. A. Immunoblot for p53 showing 
successful p53 knockdown in p53 shRNA lentivirally infected HEK cells in both the cytosolic 
and membrane fractions of the lysate. B. p53 immunostaining showing p53 significantly knocked 
down in p53 shRNA lentivirally infected HEK cells (A568 marking p53). Scale bar = 50 µm. 
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Figure 3. K43G CaMK-II inhibits cell growth in the presence of p53. DAPI staining was 
performed on HEK cells 48 hours after transfected with either K43G or WT CaMK-II. Total cells 
were counted and the percent difference between WT and K43G cells was calculated. p53 
deficient cells were more growth inhibited compared to control cells. Graph represents the data 
from three separate experiments. Asterisk indicates p-value < 0.05.  
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Figure 4. HEK cell growth is inhibited by KN-93 induced CaMK-II inhibition, but is not more 
sensitive in the absence of p53. A. Cells were counted when plated (Day 1) and 24 hours after 
KN-93 drug treatment (Day 2). Cell number did not increase in comparison to control when 
exposed to 10µM KN-93 for 24 hours (magnification = 20x).  B. Cells were DAPI stained and 
counted 48 hours post KN-93 drug treatment. The percent difference of total cells was compared 
between KN-93 treated cells and untreated cells and showed no difference in p53 deficient cells. 
C. The percent increase of total cells from plated to 24 hours post treatment for each condition 
was calculated and analyzed. There was evidence of growth inhibition in cells treated with 10µM 
KN-93 for 24 hours. KN-93 was added in the amounts indicated (µM). Graphs represent the data 
from three separate experiments. 
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A.  
     
B.  
 
Figure 5. Dominant negative K43G/K43A CaMK-II expression forms small aggregates in both 
HEK and mPCT cells. A. FLAG-GFP δe CaMK-II K43G, WT.  Images showing aggregates 
forming in both WT and K43G CaMK-II transfected HEK cells. More aggregates form in 
dominant negative K43G CaMK-II transfected cells (arrows; magnification = 60x). B. FLAG-
GFP δe CaMK-II K43A, WT.  Images showing aggregates forming only in dominant negative 
K43A CaMK-II transfected mPCT cells (arrows; magnification = 20x).GFP is green fluorescent 
protein marking CaMK-II and DAPI  marking cell nuclei. PC is phase contrast, DAPI is marking 
the nucleus, and GFP is green fluoresecent protein marking CaMK-II constructs. Top scale bar = 
50 µm. Bottom scale bar = 100 µm. 
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Figure 6. Less CaMK-II aggregates form in absence of p53. A. HEK siRNA transfection of 
either p53 siRNA or p53 scrambled siRNA co-transfected with WT or K43G CaMK-II fixed at 24 
and 48 hours. Significantly more aggregation occurs in p53 deficient cells.   B. Percentage of 
aggregates out of all transfected cells with WT or K43G CaMK-II fixed at 48 hours in the stable 
p53 knockdown HEK cells. CaMK-II aggregation increases in the absence of p53. Graphs 
represent the data from three separate experiments. Asterisks = p-value < 0.05.  
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Figure 7. K43G CaMK-II aggregates might not be associated with the mitochondrial p53-
pathway.  Dominant negative K43G CaMK-II (GFP) and mitochondria stained (MitoTracker) do 
not co-localize in the cytosol of HEK cells (magnification = 60x; scale bar = 50 µm).  
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Figure 8. The interaction between CaMK-II and p53 does not involve the initiation of 
apoptosis. HEK cells transfected with K43G CaMK-II (GFP) does not show any evidence of 
chromatin fragmentation (DAPI). Scale bar = 50 µm. 
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Figure 9. Model for the CaMK-II and p53 interaction. Catalytically inactive CaMK-II does not 
phosphorylate and thus cannot inactivate GSK-3α or GSK-3β. Activated GSK-3β enters the 
nucleus, down regulates SKP2 expression decreasing its inhibition on p27Kip1. As a result, 
stabilized p27Kip1 binds to Cdk2 causing G0/G1 cell cycle arrest. The mechanism describing how 
and why p53 is exported from the nucleus and is trapped by CaMK-II still remains unclear. 
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